Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | NPY1R | P25929 | 12/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14035764 | 0.82 | HRH1 (0.41) | NPY1RPTPN1CYP2D6CHRM1HTR2A | |
| SCHEMBL9394591 | 0.82 | CNR2 (0.43) | LOXL2NPY1RPTPN1CNR2GPR3 | |
| SCHEMBL14035702 | 0.81 | LOXL2 (0.39) | LOXL2NPY1RPTPN1CNR2GPR3 | |
| SCHEMBL22263115 | 0.79 | GPR3 (0.46) | LOXL2NPY1RPTPN1CNR2GPR3 | |
| SCHEMBL717815 | 0.76 | CNR2 (0.34) | PLK1LOXL2CNR2CYP2D6CHRM1 | |
| SCHEMBL29513021 | 0.69 | ALDH1A1 (0.59) | PLK1 | |
| SCHEMBL22909024 | 0.69 | ALDH1A1 (0.59) | PLK1 | |
| SCHEMBL23132153 | 0.69 | GPR3 (0.46) | LOXL2GPR3CYP2D6CHRM1HTR2A | |
| SCHEMBL31499102 | 0.69 | GPR3 (0.46) | LOXL2GPR3CYP2D6CHRM1HTR2A | |
| SCHEMBL14045624 | 0.69 | CNR2 (0.46) | LOXL2NPY1RPTPN1CNR2GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897781-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-20080287398-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080027029-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027029-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | PLK1 3507/4885LOXL2 2047/4885NPY1R 213/4885 |
| US-20080287398-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | PLK1 3507/4885LOXL2 2047/4885NPY1R 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.